Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pyxis Oncology (PYXS) Income towards Parent Company: 2024-2025

Historic Income towards Parent Company for Pyxis Oncology (PYXS) over the last 2 years, with Sep 2025 value amounting to -$22.0 million.

  • Pyxis Oncology's Income towards Parent Company fell 3.77% to -$22.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$100.4 million, marking a year-over-year change of. This contributed to the annual value of -$77.3 million for FY2024, which is 4.66% down from last year.
  • According to the latest figures from Q3 2025, Pyxis Oncology's Income towards Parent Company is -$22.0 million, which was down 3.99% from -$21.2 million recorded in Q2 2025.
  • In the past 5 years, Pyxis Oncology's Income towards Parent Company ranged from a high of -$3.3 million in Q2 2024 and a low of -$35.6 million during Q4 2024.
  • Its 2-year average for Income towards Parent Company is -$18.4 million, with a median of -$21.2 million in 2024.
  • Data for Pyxis Oncology's Income towards Parent Company shows a maximum YoY plummeted of 549.82% (in 2025) over the last 5 years.
  • Pyxis Oncology's Income towards Parent Company (Quarterly) stood at -$35.6 million in 2024, then fell by 3.77% to -$22.0 million in 2025.
  • Its Income towards Parent Company stands at -$22.0 million for Q3 2025, versus -$21.2 million for Q2 2025 and -$21.7 million for Q1 2025.